drugset
drugset / Trial / NCT06621615

Clinical Study of CVL006 Injection in Advanced Solid Tumors

NCT06621615 ↗

Phase 1 Not yet recruiting 120 enrolled Convalife (Shanghai) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum tolerated dose (MTD), and recommend the dosage for phase II clinical trials (RP2D).

Timeline

Start
2024-11-20
Primary completion
2028-05-20
Completion
2028-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CVL006 Monoclonal antibody 0.03 mg/kg Intravenous

Indications

No indication recorded.